Tag

Quarterly Results

All articles tagged with #quarterly results

Berkshire Breaks Long Selling Streak With $23.5B Q2 Stock Buy, Including $10B Alphabet Private Placement
business22 days ago

Berkshire Breaks Long Selling Streak With $23.5B Q2 Stock Buy, Including $10B Alphabet Private Placement

Berkshire Hathaway ended a 14-quarter net-selloff by buying about $23.5 billion of stocks in the second quarter, including roughly $10 billion of Alphabet shares purchased directly from Alphabet in a private placement at about $351.81 for Class A and $348.20 for Class C, cheaper than the public pricing. Alphabet becomes a major Berkshire holding, alongside other large stakes, while Berkshire’s cash pile fell to about $365.5 billion; the quarter also included notable activity like the Taylor Morrison deal and higher buybacks.

Disney Parks Roars to Record Revenue Amid Travel Slowdown
business26 days ago

Disney Parks Roars to Record Revenue Amid Travel Slowdown

Disney’s experiences segment (parks, cruises, resorts) posted nearly $10 billion in Q3 revenue, a 10% year-over-year gain and a quarterly record, with operating income above $3 billion. Domestic attendance rose and guest spending increased, aided by promotions and refreshed attractions, while two new ships boosted cruise capacity and resorts revenue. Despite a 6% drop in international travel to the U.S., Disney says it is outperforming competitors in parks and maintains momentum through marketing and promotions.

Merck Q2 2026 Highlights: Oncology Momentum, FDA Wins, and Terns Deal Reshapes Guidance
business27 days ago

Merck Q2 2026 Highlights: Oncology Momentum, FDA Wins, and Terns Deal Reshapes Guidance

Merck posted 2Q26 sales of about $16.6B with KEYTRUDA/KEYTRUDA QLEX driving growth alongside WINREVAIR and Animal Health, while a $2.31 per-share charge tied to the Terns acquisition weighed on GAAP earnings and led to a narrowed full-year outlook of $66.3–$67.3B in sales and $2.66–$2.76 in non-GAAP EPS. The company highlighted FDA approvals for LIPFENDRA and several positive Phase 3 results across its oncology and HIV programs, plus continued progress across vaccines, immunology, and other pipeline milestones, including TroFuse-005 in endometrial cancer and ISL/LEN HIV regimens, as it advances its 2026 strategic plan.

business1 month ago

Bloom Energy posts record Q2 revenue and raises 2026 outlook

Bloom Energy reported a record Q2 2026 revenue of $1.065 billion (up 165% year over year, with product revenue up 215%), improved gross margins, and solid operating cash flow as it raised full-year 2026 revenue guidance to $3.9 billion to $4.2 billion. Non-GAAP EPS rose to $0.78, GAAP EPS was $0.62, and GAAP net income to common stockholders was about $196 million, signaling profitable growth driven by strong demand for its onsite power solutions, including AI/data-center deployments.

CrowdStrike Climbs on Q1 FY2027 Results, Boosts ARR Guidance and Announces 4-for-1 Stock Split
business2 months ago

CrowdStrike Climbs on Q1 FY2027 Results, Boosts ARR Guidance and Announces 4-for-1 Stock Split

CrowdStrike reported Q1 FY2027 revenue of $1.39B (up 26%), ARR of $5.51B (up 24%), and record Q1 net new ARR of $256M, along with record cash flow from operations of $590.9M and free cash flow of $468.5M. Non-GAAP operating income was $325.7M and non-GAAP net income $283.4M, while GAAP net income was $27.8M. The company raised its full-year non-GAAP net new ARR growth outlook to 27.7% at the midpoint and provided FY27 revenue guidance of about $5.91-$5.96B and non-GAAP EPS of $4.88-$4.96. It also announced a four-for-one stock split, effective July 2, 2026, and highlighted AI-driven platform momentum, QuiltWorks collaboration with OpenAI/Anthropic, and Falcon platform expansions.

business6 months ago

Broadcom's Q1 FY2026 Revenue Climbs on AI Demand, Announces Dividend and $10B Buyback

Broadcom posted Q1 FY2026 revenue of $19.3B (up 29% YoY) with GAAP net income of $7.35B and non-GAAP net income of $10.19B; adjusted EBITDA was $13.13B (68% of revenue) and diluted EPS was $1.50 (GAAP) or $2.05 (non-GAAP). Operating cash flow reached $8.26B and free cash flow $8.01B. The Board approved a quarterly dividend of $0.65 per share and a new $10B share repurchase program. For Q2 FY2026, revenue guidance is about $22.0B with ~68% Adjusted EBITDA. AI-driven revenue was $8.4B in Q1 (up 106% YoY) and is expected to hit ~$10.7B in Q2. Semiconductors led with $12.515B of revenue; infrastructure software contributed $6.796B. The company finished the quarter with $14.174B in cash and $63.8B in long‑term debt.

Delta Air Lines posts strong 2025 results with optimistic 2026 outlook
business7 months ago

Delta Air Lines posts strong 2025 results with optimistic 2026 outlook

Delta Air Lines reported Q4 2025 revenue of $16.0B and full-year $63.4B, with Q4 operating income of $1.5B (9.2% margin) and full-year $5.8B (9.2%); GAAP EPS was $1.86 in Q4 and $7.66 for 2025, and operating cash flow was $2.3B in Q4 and $8.3B for the year. The airline highlighted $5B pre-tax profit, record $4.6B free cash flow, $1.3B profit sharing, and guided about 20% earnings growth in 2026, with debt and finance leases totaling $14.1B at year-end.

Prologis Surges Ahead with Record Leasing and Upbeat Outlook
business10 months ago

Prologis Surges Ahead with Record Leasing and Upbeat Outlook

Prologis reported a record 62 million square feet of lease signings in Q3 2025, with strong operational metrics and expansion into data centers, supported by a solid pipeline and limited new supply. The company issued $2.3 billion in debt, maintained a strong liquidity position, and raised its earnings guidance for 2025, reflecting confidence in continued growth.